281 related articles for article (PubMed ID: 34731493)
1. Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.
Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
Int J Dermatol; 2022 Aug; 61(8):1029-1033. PubMed ID: 34731493
[TBL] [Abstract][Full Text] [Related]
2. Guselkumab: Mid-term effectiveness, drug survival, and safety in real clinical practice.
Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Galán-Gutiérrez M
Dermatol Ther; 2021 Mar; 34(2):e14798. PubMed ID: 33484067
[TBL] [Abstract][Full Text] [Related]
3. Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.
Ruiz-Villaverde R; Vasquez-Chinchay F; Rodriguez-Fernandez-Freire L; C Armario-Hita J; Pérez-Gil A; Galán-Gutiérrez M
Life (Basel); 2022 Sep; 12(9):. PubMed ID: 36143449
[TBL] [Abstract][Full Text] [Related]
4. Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation.
Herranz-Pinto P; Alonso-Pacheco ML; Feltes-Ochoa R; Mayor-Ibarguren A; Servera-Negre G; Busto-Leis JM; Gonzalez-Fernández MA; Herrero-Ambrosio A
Clin Drug Investig; 2023 Jul; 43(7):517-527. PubMed ID: 37402097
[TBL] [Abstract][Full Text] [Related]
5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
6. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis.
Ruiz-Villaverde R; Rodriguez-Fernandez-Freire L; Armario-Hita JC; Pérez-Gil A; Chinchay FV; Galán-Gutiérrez M
Dermatol Ther; 2022 Oct; 35(10):e15760. PubMed ID: 35971573
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
[TBL] [Abstract][Full Text] [Related]
8. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
10. Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial.
Puig L; Costanzo A; de Jong EMGJ; Torres T; Warren RB; Wapenaar R; Wegner S; Gorecki P; Gramiccia T; Jazra M; Buyze J; Conrad C
Am J Clin Dermatol; 2024 Mar; 25(2):315-325. PubMed ID: 37804472
[TBL] [Abstract][Full Text] [Related]
11. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
Galluzzo M; Talamonti M; Bernardini N; Chiricozzi A; De Simone C; Bonifati C; Bruni P; Diotallevi F; Esposito M; Graceffa D; Hansel K; Loconsole F; Moretta G; Mugheddu C; Papini M; Richetta A; Skroza N; Atzori L; Fargnoli MC; Persechino S; Offidani A; Stingeni L; Peris K; Potenza C; Bianchi L
Expert Opin Biol Ther; 2022 Dec; 22(12):1585-1592. PubMed ID: 35708257
[TBL] [Abstract][Full Text] [Related]
13. Absolute Psoriasis Area and Severity Index as a valuable marker to determine initial treatment response in psoriasis patients treated with guselkumab in routine clinical care.
Seidl U; Pinter A; Wilsmann-Theis D; Poortinga S; Morrison K; Mrowietz U; Gerdes S
Dermatol Ther; 2022 Jan; 35(1):e15193. PubMed ID: 34741783
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E; López-Ferrer A; Martínez-Doménech Á; Ruiz-Villaverde R; Llamas-Velasco MDM; Rocamora V; Julià M; Notario J; Fernández-Freire LR; Sahuquillo-Torralba A; Vidal D; Rivera R; Carretero G; Mateu A; de la Cueva P; Carrascosa JM
Dermatol Ther; 2022 Feb; 35(2):e15231. PubMed ID: 34820971
[TBL] [Abstract][Full Text] [Related]
15. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
[TBL] [Abstract][Full Text] [Related]
16. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany.
Augustin M; Wirth D; Mahlich J; Pepper AN; Druchok C
J Dermatolog Treat; 2022 Mar; 33(2):976-982. PubMed ID: 32663067
[TBL] [Abstract][Full Text] [Related]
17. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K;
Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
[TBL] [Abstract][Full Text] [Related]
19. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
Blauvelt A; Armstrong AW; Langley RG; Gebauer K; Thaçi D; Bagel J; Guenther LC; Paul C; Randazzo B; Flavin S; Hsu MC; You Y; Reich K
J Dermatolog Treat; 2022 Jun; 33(4):2317-2324. PubMed ID: 34348574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
